報價延遲最少15分鐘:2026/04/23 19:59 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.215 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-16.38/--
|
|
企業價值
1.12M
|
| 資產負債 |
|
每股賬面淨值
-1.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.20K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery. |
